financetom
Business
financetom
/
Business
/
EnerSys Raises Fiscal Q3, 2025 Guidance; Shares Gain After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EnerSys Raises Fiscal Q3, 2025 Guidance; Shares Gain After Hours
Dec 17, 2024 2:38 PM

05:19 PM EST, 12/17/2024 (MT Newswires) -- EnerSys ( ENS ) said late Tuesday it is raising its adjusted earnings guidance for fiscal Q3 and 2025 due to incremental benefits from tax credits.

The company updated its fiscal Q3 adjusted earnings outlook to $3.00 to $3.10 per diluted share from $2.20 to $2.30, previously. Analysts polled by FactSet expect $2.23.

EnerSys ( ENS ) also raised fiscal 2025 adjusted earnings guidance to $9.65 to $9.95 per diluted share from the previous outlook of $8.75 to $9.05. Analysts polled by FactSet expect $8.85.

Shares of the company were up 3.8% in after-hours activity.

Price: 95.00, Change: +3.47, Percent Change: +3.79

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
DeepSeek's 'Sputnik moment' prompts investors to sell big AI players
DeepSeek's 'Sputnik moment' prompts investors to sell big AI players
Jan 27, 2025
LONDON/SINGAPORE, Jan 27 (Reuters) - Investors hammered technology stocks on Monday, sending the likes of Nvidia ( NVDA ) and Oracle plummeting, as the emergence of a low-cost Chinese artificial intelligence model cast doubts on Western companies' dominance in this sector. Startup DeepSeek last week launched a free assistant it says uses less data at a fraction of the cost...
Emerson to buy rest of AspenTech for $265 per share
Emerson to buy rest of AspenTech for $265 per share
Jan 27, 2025
Jan 27 (Reuters) - Emerson Electric ( EMR ) will acquire all outstanding shares of AspenTech it does not already own for $265 per share, the companies said on Monday. ...
Veru's experimental drug helps Wegovy patients preserve muscle in study
Veru's experimental drug helps Wegovy patients preserve muscle in study
Jan 27, 2025
Jan 27 (Reuters) - Veru ( VERU ) said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage study. The study was testing Veru's ( VERU ) oral drug, enobosarm, in patients aged 60 and above. The drug targets androgen hormones,...
Before Trump's return, some top U.S. firms had already gone cold on diversity pledges
Before Trump's return, some top U.S. firms had already gone cold on diversity pledges
Jan 27, 2025
LONDON (Reuters) - Some large U.S. companies had made limited progress in promoting women and were diluting or abandoning equal opportunity initiatives even before President Donald Trump launched last week a nationwide campaign to scrap them, underscoring a shift in corporate priorities. Shortly after taking office on Jan. 20, Trump issued sweeping executive orders to dismantle diversity, equity and inclusion...
Copyright 2023-2026 - www.financetom.com All Rights Reserved